Conivaptan hydrochloride

Conivaptan hydrochloride (pronunciation: koh-ni-VAP-tan hy-dro-KLOR-ide) is a non-peptide inhibitor of the vasopressin receptor, specifically the V1A and V2 receptors. It is used in the treatment of hyponatremia (low blood sodium levels) associated with heart failure, cirrhosis, and Syndrome of Inappropriate Antidiuretic Hormone (SIADH).

Etymology

The name "Conivaptan" is derived from the Latin words 'coni' meaning 'together' and 'vaptan' meaning 'to bind'. The 'hydrochloride' part of the name refers to the hydrochloride salt form of the drug, which enhances its solubility and stability.

Pharmacology

Conivaptan hydrochloride works by blocking the action of vasopressin, a hormone that regulates the body's water balance. By inhibiting the vasopressin receptors, conivaptan hydrochloride increases urine production, thereby helping to correct low sodium levels in the blood.

Usage

Conivaptan hydrochloride is typically administered intravenously in a hospital setting under the supervision of a healthcare professional. The dosage and duration of treatment are determined based on the patient's medical condition and response to therapy.

Side Effects

Common side effects of conivaptan hydrochloride include dry mouth, thirst, and increased urination. Serious side effects may include rapid heartbeat, mood changes, muscle cramps, and seizures. Patients are advised to seek immediate medical attention if they experience any serious side effects.

Related Terms

External links

Medical encyclopedia article on Conivaptan hydrochloride
Wikipedia's article - Conivaptan hydrochloride

This WikiMD dictionary article is a stub. You can help make it a full article.

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski